Viventia biotech reports synergistic effect of its Proxinium(TM) antibody in combination with chemotherapy and radiation



    - Results Reported at the American Association for Cancer Research (AACR)
    Annual Meeting -

    TORONTO, April 18 /CNW/ - Viventia Biotech Inc., a privately held
biopharmaceutical company advancing a portfolio of novel antibody products
focused on cancer, today announced results of in vitro cytotoxicity and in
vivo pharmacokinetic studies conducted to evaluate the potential for combining
its phase III anti-cancer antibody therapeutic, Proxinium(TM), with first-line
standard of care therapy for squamous cell carcinoma of the head & neck
(SCCHN). The data were presented at the Annual Meeting of the American
Association for Cancer Research (AACR), which runs from April 14-18, 2007 in
Los Angeles, California.
    Viventia's lead product, Proxinium(TM), is being developed to treat late
stage, locally advanced head and neck cancer and is currently enrolling
patients in its TARGET trial, a pivotal Phase III global clinical trial that
is expected to complete accrual by the end of 2007. Proxinium(TM) targets the
cancer antigen EpCAM.
    The combination of Proxinium(TM) with cisplatin, carboplatin, paclitaxel,
5-fluorouracil, and docetaxel resulted in a significant additive cytotoxic
effect (p (less than) 0.05) as compared to the chemotherapeutic agents
administered alone. The sequence of drug administration did not influence the
outcome. The combination of Proxinium(TM) with radiotherapy led to a
synergistic cytotoxic effect when Proxinium(TM) was administered after
radiotherapy or additive effects when Proxinium(TM) was administered before or
at the same time as radiotherapy.
    "The data from these studies clearly demonstrate the additive cytotoxic
effect of Proxinium(TM) when used either in combination with chemotherapeutic
agents or with radiation therapy," said Dr. Barry Wenig, Head of
Otolaryngology - Head and Neck Cancer at Evanston Northwestern Healthcare
Centre. "These data offer exciting possibilities for the use of Proxinium(TM)
not solely as a local immunotherapy, but more importantly as an adjunct to the
current first-line therapies and even as a precursor to surgery."
    Dr. Nick Glover, President and CEO of Viventia Biotech Inc. commented:
"Our development strategy for Proxinium(TM) is to aggressively pursue initial
approval for the treatment of late stage, palliative head and neck cancer, to
be followed by a broad clinical program intended to support the addition of
Proxinium(TM) to standard chemotherapy, radiotherapy and chemoradiotherapy
regimens for earlier lines of treatment. These data presented at AACR clearly
show the significant promise of adding Proxinium(TM) to other treatment
modalities in head and neck cancer. Our goal is to establish Proxinium(TM) as
a key component in the multidisciplinary treatment of this devastating
disease."
    In vitro cytotoxicity was evaluated pre-, concurrent and post-treatment
with Proxinium(TM) in SCCHN cell lines CAL 27 and SCC-15. Cell growth
inhibition, in combination with various chemotherapeutic agents (cisplatin,
carboplatin, paclitaxel, 5-fluorouracil, docetaxel, bleomycin, and
methotrexate) was assessed using an MTS assay. Growth inhibition, in
combination with radiotherapy, was assessed using a clonogenic assay. In vivo
pharmacokinetic profiles generated from drug administration to Sprague-Dawley
rats indicated that the pharmacokinetics of cisplatin, paclitaxel, and
5-fluorouracil was not affected when administered in combination with
Proxinium(TM). In summary, no antagonism was observed in in vitro or in vivo
studies with Proxinium(TM) in combination with either chemo- or radiotherapy.
The additive and synergistic cytotoxic effects demonstrated in this study
indicate the potential utility of Proxinium(TM) in conjunction with more
conventional treatment modalities for patients with SCCHN and suggest that
Proxinium(TM) in conjunction with first line standard of care therapy may be
of greater benefit than standard care alone.
    Viventia Biotech retains full global product rights to Proxinium(TM). The
Company is seeking partners for Proxinium(TM) capable of complementing
Viventia's development expertise with their global sales, marketing and
commercial capabilities.

    About Viventia Biotech:
    Viventia Biotech Inc. is a biopharmaceutical company generating a
pipeline of fully human antibodies and identifying novel targets for the
treatment of cancer. Its lead products have been further developed into Armed
Antibodies(TM); powerful and precise anti-cancer drugs that combine cytotoxic
protein payloads with the highly precise tumor-targeting characteristics of
monoclonal antibodies to overcome various forms of cancer. Viventia's lead
product, Proxinium(TM), is undergoing a global Phase III clinical trial -
TARGET - for the treatment of head and neck cancer. Viventia is also
developing Vicinium(TM), which is in a Phase II clinical study for the
treatment of bladder cancer, and VB6-845, beginning a Phase I/II clinical
trial for the treatment of solid tumors. The Company has created a portfolio
of follow-on fully human antibody drug candidates and has a discovery engine
to provide a rich and sustainable long-term pipeline.




For further information:

For further information: James Smith, Tel. (416) 815-0700 x 229, Fax.
(416) 815-0080, Email: jsmith@viventia.com, www.viventia.com,
www.proxinium.com

Organization Profile

VIVENTIA BIOTECH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890